CLINICAL STUDY
Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia
Michael H. Davidson, MD, FACC*,*,
Thomas McGarry, MD, FACC ,
Robert Bettis, MD ,
Lorenzo Melani, MD, PhD ,
Leslie J. Lipka, MD, PhD, FACC,
Alexandre P. LeBeaut, MD,
Ramachandran Suresh, PhD,
Steven Sun, PhD,
Enrico P. Veltri, MD, FACC Ezetimibe Study Group
* Chicago Center for Clinical Research, Chicago, Illinois, USA
Oklahoma Foundation for Cardiovascular Research, Oklahoma City, Oklahoma, USA
Clinical Research Advantage, Edmonds Family Medicine Clinic, Edmonds, Washington, USA
Schering-Plough Research Institute, Kenilworth, New Jersey, USA
Manuscript received April 11, 2002;
revised manuscript received September 6, 2002,
accepted September 20, 2002.
* Reprint requests and correspondence: Dr. Michael H. Davidson, Chicago Center for Clinical Research, 515 North State Street, Suite 2700, Chicago, Illinois 60610-4324 USA.
mdavidson{at}protocare.com
OBJECTIVES: The purpose of this study was to assess the efficacy and safety of ezetimibe administered with simvastatin in patients with primary hypercholesterolemia.
BACKGROUND: Despite the availability of statins, many patients do not achieve lipid targets. Combination therapy with lipid-lowering agents that act via a complementary pathway may allow additional patients to achieve recommended cholesterol goals.
METHODS: After dietary stabilization, a 2- to 12-week washout period, and a 4-week, single-blind, placebo lead-in period, patients with baseline low-density lipoprotein cholesterol (LDL-C)  145 mg/dl to  250 mg/dl and triglycerides (TG) 350 mg/dl were randomized to one of the following 10 groups administered daily for 12 consecutive weeks: ezetimibe 10 mg; simvastatin 10, 20, 40, or 80 mg; ezetimibe 10 mg plus simvastatin 10, 20, 40, or 80 mg; or placebo. The primary efficacy variable was percentage reduction from baseline to end point in direct LDL-C for the pooled ezetimibe plus simvastatin groups versus pooled simvastatin groups.
RESULTS: Ezetimibe plus simvastatin significantly improved LDL-C (p < 0.01), high-density lipoprotein cholesterol (HDL-C) (p = 0.03), and TG (p < 0.01) compared with simvastatin alone. Ezetimibe plus simvastatin (pooled doses) provided an incremental 13.8% LDL-C reduction, 2.4% HDL-C increase, and 7.5% TG reduction compared with pooled simvastatin alone. Coadministration of ezetimibe and simvastatin provided LDL-C reductions of 44% to 57%, TG reductions of 20% to 28%, and HDL-C increases of 8% to 11%, depending on the simvastatin dose. Ezetimibe 10 mg plus simvastatin 10 mg and simvastatin 80 mg alone each provided a 44% LDL-C reduction. The coadministration of ezetimibe with simvastatin was well tolerated, with a safety profile similar to those of simvastatin and of placebo.
CONCLUSIONS: When coadministered with simvastatin, ezetimibe provided significant incremental reductions in LDL-C and TG, as well as increases in HDL-C. Coadministration of ezetimibe with simvastatin was well tolerated and comparable to statin alone.
|
Abbreviations and Acronyms
| | ALT | | alanine aminotransferase | | AST | | aspartate aminotransferase | | CPK | | creatine phosphokinase | | HDL-C | | high-density lipoprotein cholesterol | | LDL-C | | low-density lipoprotein cholesterol | | NCEP ATP | | National Cholesterol Education Program Adult Treatment Panel | | TC | | total cholesterol | | TG | | triglycerides | | ULN | | upper limit of normal |
|
This article has been cited by other articles:
|
|
|
|
 
A. J Tremblay, B. Lamarche, J.-C. Hogue, and P. Couture
Effects of ezetimibe and simvastatin on apolipoprotein B metabolism in males with mixed hyperlipidemia
J. Lipid Res.,
July 1, 2009;
50(7):
1463 - 1471.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. J. Al Badarin, I. J. Kullo, S. L. Kopecky, and R. J. Thomas
Impact of Ezetimibe on Atherosclerosis: Is the Jury Still Out?
Mayo Clin. Proc.,
April 1, 2009;
84(4):
353 - 361.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. van der Graaf, C. Cuffie-Jackson, M. N. Vissers, M. D. Trip, C. Gagne, G. Shi, E. Veltri, H. J. Avis, and J. J.P. Kastelein
Efficacy and Safety of Coadministration of Ezetimibe and Simvastatin in Adolescents With Heterozygous Familial Hypercholesterolemia
J. Am. Coll. Cardiol.,
October 21, 2008;
52(17):
1421 - 1429.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Kinlay
Vascular form and function: two mechanisms for cardiovascular prevention
Eur. Heart J.,
July 2, 2008;
29(14):
1711 - 1713.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J Armitage
Commentary on NICE technology appraisal guidance on ezetimibe for the treatment of primary (heterozygous-familial and non-familial) hypercholesterolaemia
Heart,
May 1, 2008;
94(5):
643 - 645.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. J.P. Kastelein, F. Akdim, E. S.G. Stroes, A. H. Zwinderman, M. L. Bots, A. F.H. Stalenhoef, F. L.J. Visseren, E. J.G. Sijbrands, M. D. Trip, E. A. Stein, et al.
Simvastatin with or without Ezetimibe in Familial Hypercholesterolemia
N. Engl. J. Med.,
April 3, 2008;
358(14):
1431 - 1443.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. B. Weinglass, M. G. Kohler, E. O. Nketiah, J. Liu, W. Schmalhofer, A. Thomas, B. Williams, L. Beers, L. Smith, M. Hafey, et al.
Madin-Darby Canine Kidney II Cells: A Pharmacologically Validated System for NPC1L1-Mediated Cholesterol Uptake
Mol. Pharmacol.,
April 1, 2008;
73(4):
1072 - 1084.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. M. Psaty and T. Lumley
Surrogate End Points and FDA Approval: A Tale of 2 Lipid-Altering Drugs
JAMA,
March 26, 2008;
299(12):
1474 - 1476.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. S Sampalis, S. Bissonnette, R. Habib, S. Boukas, and for the Ezetrol Add-On Investigators
Reduction in Estimated Risk for Coronary Artery Disease After Use of Ezetimibe with a Statin
Ann. Pharmacother.,
September 1, 2007;
41(9):
1345 - 1351.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. H. Davidson and J. G. Robinson
Safety of Aggressive Lipid Management
J. Am. Coll. Cardiol.,
May 1, 2007;
49(17):
1753 - 1762.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. E. Hawes, K. A. O'Neill, X. Yao, J. H. Crona, H. R. Davis Jr., M. P. Graziano, and S. W. Altmann
In Vivo Responsiveness to Ezetimibe Correlates with Niemann-Pick C1 Like-1 (NPC1L1) Binding Affinity: Comparison of Multiple Species NPC1L1 Orthologs
Mol. Pharmacol.,
January 1, 2007;
71(1):
19 - 29.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Kashani, C. O. Phillips, J. M. Foody, Y. Wang, S. Mangalmurti, D. T. Ko, and H. M. Krumholz
Risks Associated With Statin Therapy: A Systematic Overview of Randomized Clinical Trials
Circulation,
December 19, 2006;
114(25):
2788 - 2797.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. A. Pearson, M. A. Denke, P. E. McBride, W. P. Battisti, R. A. Gazzara, W. E. Brady, and J. Palmisano
Effectiveness of Ezetimibe Added to Ongoing Statin Therapy in Modifying Lipid Profiles and Low-Density Lipoprotein Cholesterol Goal Attainment in Patients of Different Races and Ethnicities: A Substudy of the Ezetimibe Add-On to Statin for Effectiveness Trial
Mayo Clin. Proc.,
September 1, 2006;
81(9):
1177 - 1185.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Fichtlscherer, C. Schmidt-Lucke, S. Bojunga, L. Rossig, C. Heeschen, S. Dimmeler, and A. M. Zeiher
Differential effects of short-term lipid lowering with ezetimibe and statins on endothelial function in patients with CAD: clinical evidence for 'pleiotropic' functions of statin therapy
Eur. Heart J.,
May 2, 2006;
27(10):
1182 - 1190.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. J. Tremblay, B. Lamarche, J. S. Cohn, J.-C. Hogue, and P. Couture
Effect of Ezetimibe on the In Vivo Kinetics of ApoB-48 and ApoB-100 in Men With Primary Hypercholesterolemia
Arterioscler. Thromb. Vasc. Biol.,
May 1, 2006;
26(5):
1101 - 1106.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. J. Bergman, J. Burke, P. Larson, A. O. Johnson-Levonas, L. Reyderman, P. Statkevich, S. E. Maxwell, T. Kosoglou, G. Murphy, K. Gottesdiener, et al.
Interaction of single-dose ezetimibe and steady-state cyclosporine in renal transplant patients.
J. Clin. Pharmacol.,
March 1, 2006;
46(3):
328 - 336.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Garcia-Calvo, J. Lisnock, H. G. Bull, B. E. Hawes, D. A. Burnett, M. P. Braun, J. H. Crona, H. R. Davis Jr., D. C. Dean, P. A. Detmers, et al.
The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1)
PNAS,
June 7, 2005;
102(23):
8132 - 8137.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. A. Pearson, M. A. Denke, P. E. McBride, W. P. Battisti, W. E. Brady, and J. Palmisano
A Community-Based, Randomized Trial of Ezetimibe Added to Statin Therapy to Attain NCEP ATP III Goals for LDL Cholesterol in Hypercholesterolemic Patients: The Ezetimibe Add-On to Statin for Effectiveness (EASE) Trial
Mayo Clin. Proc.,
May 1, 2005;
80(5):
587 - 595.
[Abstract]
[PDF]
|
|
|
|
|
|
|
{blacktriangledown}Ezetimibe - a new cholesterol-lowering drug
DTB,
September 1, 2004;
42(9):
65 - 67.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. J. Chilton
Coadministration Therapy in Hypercholesterolemia: A Novel Approach to Achieving Lipid Goals--Introduction
J Am Osteopath Assoc,
September 1, 2004;
104(9_suppl):
3S - 4S.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. Denke
Coadministration of Multidrug Therapy to Achieve Lipid Goals
J Am Osteopath Assoc,
September 1, 2004;
104(9_suppl):
17S - 22S.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. J. Vaughan and A. M. Gotto Jr
Update on Statins: 2003
Circulation,
August 17, 2004;
110(7):
886 - 892.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. M. Grundy, J. I. Cleeman, C. N. Bairey Merz, H. B. Brewer Jr, L. T. Clark, D. B. Hunninghake, R. C. Pasternak, S. C. Smith Jr, N. J. Stone, and Coordinating Committee of the National Cholesterol
Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines
J. Am. Coll. Cardiol.,
August 4, 2004;
44(3):
720 - 732.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. M. Grundy, J. I. Cleeman, C. N. B. Merz, H. B. Brewer Jr, L. T. Clark, D. B. Hunninghake, R. C. Pasternak, S. C. Smith Jr, N. J. Stone, for the Coordinating Committee of the National Cho, et al.
Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines
Arterioscler. Thromb. Vasc. Biol.,
August 1, 2004;
24(8):
e149 - e161.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. R Thompson
Management of dyslipidaemia
Heart,
August 1, 2004;
90(8):
949 - 955.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. M. Grundy, J. I. Cleeman, C. N. B. Merz, H. B. Brewer Jr, L. T. Clark, D. B. Hunninghake, R. C. Pasternak, S. C. Smith Jr, N. J. Stone, for the Coordinating Committee of the National Cho, et al.
Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines
Circulation,
July 13, 2004;
110(2):
227 - 239.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Schachter
Low-dose statins: useful and safe?
The British Journal of Diabetes & Vascular Disease,
July 1, 2004;
4(4):
260 - 262.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A. Rees
Review: Ezetimibe -- clinical and pharmacological profile
The British Journal of Diabetes & Vascular Disease,
May 1, 2004;
4(3):
163 - 171.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A. C. Goldberg, A. Sapre, J. Liu, R. Capece, Y. B. Mitchel, and Ezetimibe Study Group
Efficacy and Safety of Ezetimibe Coadministered With Simvastatin in Patients With Primary Hypercholesterolemia: A Randomized, Double-Blind, Placebo-Controlled Trial
Mayo Clin. Proc.,
May 1, 2004;
79(5):
620 - 629.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R. Fux, K. Morike, U.-F. Gundel, R. Hartmann, and C. H. Gleiter
Ezetimibe and Statin-Associated Myopathy
Ann Intern Med,
April 20, 2004;
140(8):
671 - 672.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. S. Stroup, M. P. Kane, and R. S. Busch
The Antilipidemic Effects of Ezetimibe in Patients With Diabetes
Diabetes Care,
October 1, 2003;
26(10):
2958 - 2959.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. H. Davidson
Efficacy of simvastatin and ezetimibe in treating hypercholesterolemia
J. Am. Coll. Cardiol.,
July 16, 2003;
42(2):
398 - 399.
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. M. Sacks
Reply
J. Am. Coll. Cardiol.,
July 16, 2003;
42(2):
399 - 399.
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Bruckert, P. Giral, and P. Tellier
Perspectives in Cholesterol-Lowering Therapy: The Role of Ezetimibe, a New Selective Inhibitor of Intestinal Cholesterol Absorption
Circulation,
July 1, 2003;
107(25):
3124 - 3128.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. A. Kreisberg and A. Oberman
Medical Management of Hyperlipidemia/Dyslipidemia
J. Clin. Endocrinol. Metab.,
June 1, 2003;
88(6):
2445 - 2461.
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. F Mauro and C. E Tuckerman
Ezetimibe for Management of Hypercholesterolemia
Ann. Pharmacother.,
June 1, 2003;
37(6):
839 - 848.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. M. Ballantyne, J. Houri, A. Notarbartolo, L. Melani, L. J. Lipka, R. Suresh, S. Sun, A. P. LeBeaut, P. T. Sager, and E. P. Veltri
Effect of Ezetimibe Coadministered With Atorvastatin in 628 Patients With Primary Hypercholesterolemia: A Prospective, Randomized, Double-Blind Trial
Circulation,
May 20, 2003;
107(19):
2409 - 2415.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Melani, R. Mills, D. Hassman, R. Lipetz, L. Lipka, A. LeBeaut, R. Suresh, P. Mukhopadhyay, E. Veltri, and for the Ezetimibe Study Group
Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial
Eur. Heart J.,
April 2, 2003;
24(8):
717 - 728.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. D. Thompson, P. Clarkson, and R. H. Karas
Statin-Associated Myopathy
JAMA,
April 2, 2003;
289(13):
1681 - 1690.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Ezetimibe: Another Drug for Lowering Cholesterol
Journal Watch Cardiology,
February 14, 2003;
2003(214):
5 - 5.
[Full Text]
|
|
|
|
|
|
|
Ezetimibe: Another Drug for Lowering Cholesterol
Journal Watch (General),
January 28, 2003;
2003(128):
1 - 1.
[Full Text]
|
|
|
|
